Table 2.
Risk of prostate cancer on fusion biopsy based on mpMRI findings in biopsy naïve patients. (10)
| Systematic Plus Targeted | ||||
|---|---|---|---|---|
| Maximum ROI grade | Negative | GS 3+3=6 | GS 3+4=7 | GS ≥ 4+3=7 |
| No lesion/grade 1-2 | 38 (68%) | 11 (20%) | 4 (7%) | 3 (5%) |
| Grade 3 | 60 (46%) | 27 (21%) | 32 (25%) | 10 (8%) |
| Grade 4 | 36 (33%) | 28 (26%) | 21 (19%) | 24 (22%) |
| Grade 5 | 1 (3%) | 5 (14%) | 8 (23%) | 21 (60%) |